Table 1.

Characteristics of post-vaccine AOSD flare case reports (TCZ, tocilizumab)

	Current case	Jeon et al. [25]	Yamamoto et al. [26]	Muench et al. [27]
Age (years)	18	34	37	23
Gender	Male	Female	Female	Female
Duration of Still’s disease (in years)	3	22	13	Around 1 year
Disease status during vaccination	Remission for 2 years	Flare free for 14 years	Remission for 2 years	Flare free for 3 months
Medications during vaccination	Methotrexate 15 mg/week	Etanercept 50 mg/week, low-dose prednisolone	Drug free	Anakinra 2 × 100 mg/day, prednisolone 5 mg/day
Type of vaccine	ChAdOx1	ChAdOx1	BNT162b2	BNT162b2
Vaccine dose	Flares after both doses	1st dose	2nd dose	1st dose
Time between vaccination and symptom onset	7 days [after 1st dose) 9 days [after 2nd dose)	9 days	Few days	6 days
Type of flare	Systemic and articular	Systemic and articular	Systemic and articular	Systemic flare, macrophage activation syndrome
Imaging	Bilateral pleural effusion	Bilateral pleural effusion, pericaridal effusion	-	Pericardial effusion
Treatment received	1st flare-prednisolone 40 mg/day 2nd flare-pulse methylprednisolone (500 mg/day for 3 days), TCZ 8 mg/kg	Pulse methylprednisolone [125 mg/day for 3 days, etanercept 50 mg sc, methotrexate 10 mg/week followed by TCZ 8 mg/kg every 2 weeks	Prednisolone 15 mg/day, TCZ 162 mg every 2 weeks for 3 doses	Methylprednisolone 250 mg/day, intravenous immunoglobulin, Anakinra 3 × 100 mg/day, oral cyclosporine 200 mg/day